**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 53913

**Manuscript Type:** REVIEW

**Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma**

Dondossola D *et al*. Diagnosis and management of pCCC

Daniele Dondossola, Michele Ghidini, Francesco Grossi, Giorgio Rossi, Diego Foschi

**Daniele Dondossola,** **Giorgio Rossi,** General and Liver Transplant Surgery Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan 20122, Italy

**Daniele Dondossola, Giorgio Rossi,** Department of Pathophysiology and Transplantation, Università degli Studi of Milan, Milan 20122, Italy

**Michele Ghidini, Francesco Grossi,** Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan 20122, Italy

**Diego Foschi,** Department of Biomedical and Clinical Sciences "Luigi Sacco", L. Sacco Hospital, Università degli Studi of Milan, Milan 20157, Italy

**Author contributions:** Dondossola D and Ghidini M drafted the paper; Dondossola D and Foschi D conceptualized the study; Grossi F reviewed the paper; Rossi G and Foschi D approved the final manuscript.

**Corresponding author: Dondossola Daniele, MD,** **Postdoctoral Fellow, Surgeon,** General and Liver Transplant Surgery Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,Via Franscesco Sforza, 35, Milan 20122, Italy. dondossola.daniele@gmail.com

**Received:** December 31, 2019

**Revised:** June 5, 2020

**Accepted:** June 19, 2020

**Published online:** July 7, 2020

**Abstract**

Cholangiocarcinoma (CCC) is the most aggressive malignant tumor of the biliary tract. Perihilar CCC (pCCC) is the most common CCC and is burdened by a complicated diagnostic iter and its anatomical location makes surgical approach burden by poor results. Besides its clinical presentation, a multimodal diagnostic approach should be carried on by a tertiary specialized center to avoid miss-diagnosis. Magnetic resonance can obtain satisfactory cholangiographic images and invasive techniques should be used if bile duct samples are needed. Preoperative staging must consider the extent of liver resection to avoid post-surgical hepatic failure. In this setting, bile duct drainage is not necessary in jaundice, while it is indicated in refractory cholangitis or when liver hypertrophy is needed. Once resecability criteria are identified, the extent of liver resection is secondary to the longitudinal spread of CCC. While in the past type IV pCCC was not considered resectable, some authors reported good results after their treatment. Conversely, in selected unresectable cases, liver transplantation could be a valuable option. Adjuvant chemotherapy is the standard of care for resected patients, conversely neoadjuvant approach has growing evidences. If curative resection is not achieved, radiotherapy can be added to chemotherapy. On the other side, patients that are not suitable for surgery must undergo bile duct decompression and chemo-radiotherapy. This multistep curative iter must be carried on in specialized centers. Hence, the aim of this review is to highlight the main steps and pitfalls of the diagnostic and therapeutic approach to pCCC with a peculiar attention to type IV pCCC.

**Key words:** Perihilar cholangiocarncioma; Liver resection; Biliary drainage; Neo-adjuvant therapy; Type IV cholangiocarcinoma; Klatskin tumor

**Citation:** Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D. Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. *World J Gastroentrol* 2020; 26(25): 3542-3561

**URL:** https://www.wjgnet.com/1007-9327/full/v26/i25/3542.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v26.i25.3542

**Core tip:** Perihilar cholangiocarncioma (pCCC) is burdened by a complicated diagnostic iter and its anatomical location makes surgical approach burden by poor results. Confounding factors, such as biliary decompression, must be avoided during diagnosis and evaluation of longitudinal extension of the tumor. While surgical advances allows the extension of surgical indication (especially for type IV pCCC and portal invasion), adjuvant chemotherapy should be administered to improve post-surgical results. Herein, a highlight on diagnostic and therapeutic management is here provided.

**INTRODUCTION**

Cholangiocarcinoma (CCC) is the most frequent and aggressive malignant tumor of the biliary tract. It arises from the epithelial cells of a bile duct and from their progenitor cells (a group of heterogeneous dynamic cells lining the biliary tree). CCC develops either within the duct or shaping a mass infiltrating the adjacent tissue (mass forming cholangiocarcinoma)[1].

CCC is commonly classified according to the site of invasion into intrahepatic and extrahepatic, itself divided into hilar/perihilar [or Klatskin tumor, perihilar CCC (pCCC)] and distal. Extrahepatic CCC are the most common among CCC[2]. pCCC is defined as CCC located in the extrahepatic biliary tree proximal to the origin of the cystic duct[3,4]. It is burdened by a complicated diagnostic iter and its anatomical location makes the surgical site less accessible, causing higher unresectable rates[5].

In this review, we will focus our attention on diagnostic and surgical approach to pCCC in order to underline the key points in its management.

**EPIDEMIOLOGY AND ETIOPATHOGENESIS**

CCC is a heterogeneous group of malignancies that represent the 3% of all gastrointestinal tumors[6]. Among CCC, 75% are extrahepatic CCC and half of them pCCC. The incidence of extrahepatic CCC varies worldwide from 0.3-3.5 per 100000 inhabitants/year in North America to 90/100000 inhabitants/year in Thailand. Among Mediterranean region, the incidence is fixed around 7.5/10000 inhabitants/year[7,8]. In Italy 5400 new cases/year are expected[9]. Extrahepatic CCC represent 1% of new neoplastic diagnosis in male and 1.4% in female, with a reduction in the female sex during the last few years[10]. The median age at diagnosis is 50 years; almost null risk is reported before 40 years, while a peak is registered around 70 years[9].

The identification of risk factors for pCCC is some-like difficult due to many reasons; first of all, papers do not often distinguish CCC into intrahepatic or extrahepatic and merge CCC with gallbladder carcinomas. Furthermore, cases are frequently isolated with no identifiable risk factors. The published risk factors can be divided in[11,12]: known: hepato/choledocholithiasis, hepatitis B and C infection, obesity, diabetes mellitus, congenital hepatic fibrosis, Caroli’s disease or choledocal cyst, primary sclerosing cholangitis (PSC), liver fluke infections (Opisthorchis viverrini and Clonorchis sinensis), intrahepatic litiasis and recurrent pyogenic cholangitis; suspect: inflammatory bowel disease, smoke, asbestos, genetic polymorphisms, diabetes.

According to these data, a surveillance program can be settled in selected patients using magnetic resonance or endoscopic-retrograde-pancreatoduodenoscopy (ERCP) (Table 1)[13–16].

The highest relative risk is identified in liver fluke infections (Opisthorchis viverrini and Clonorchis sinensis), endemic in South-East Asia[17]. Infection spreads after the ingestion of contaminated fish; and then the flukes colonize biliary tree causing chronic infection and inflammation.

Even if the mechanisms causing the transformation of cholangiocyte into neoplastic cells are nowadays unknown, CCC development in PSC is widely investigated. The risk for patients affected by PSC (as well as other diseases of biliary plate, *e.g.* Caroli’s disease) to develop CCC in their lifetime is around 3%-30%[15]. Pancreatic enzymes reflux, cholestasis and chronic inflammation leads to cholangiocyte activation, apoptosis, progression of senescence pathways and increased cellular turnover. All these mechanisms are involved in carcinogenesis: some studies underline a common pathway (interleukin 6, cyclooxygenase-2, nitric oxide, *etc*) between inflammation and malignant cellular proliferation acting on hepatic progenitor cells[18–20]. Together with this pathogenetic theory, an alternative carcinogenetic mechanism has been introduced: it is based on mitogenic pathway activation with a consequent multistep tumoral development[21]. These two mechanisms cannot be considered mutually exclusive. Indeed, in PSC patients the presence of cholangiocyte dysplasia was demonstrated together with CCC. The analyses of CCC specimens underlined a wide heterogeneity of gene mutations, however they seem to be polled according to a geographical distribution[22].

**CLASSIFICATION AND STAGING**

***Macrosopic classification***

The Bismuth classification, after modified by Corlette, is well known between general surgeons (Figure 1)[23]. It is used to try to define the correct surgical approach and it is based on macroscopic tumor appearance at the pre-surgical imaging. Although this classification is largely used in literature, it has different limits: the absence of longitudinal description of the cancer extension, no relation with prognostic data, and no clearly defined resectability criteria[24,25]. Other classifications have been proposed (*e.g.,* Memorial Sloan-kattering Cancer Centre) but none of them supplanted the use of the Bismuth-Corlette one.

On the other hand, tumor-node-metastasis (TNM) classification is worldwide accepted to define the prognosis[4]. Since the 7th edition of America Joint Commission on Cancer (AJCC) classification, pCCC has been recognized as a separate disease from the distal CCC. Unfortunately, hystopathological evaluation of surgical specimen, together with pre-operative imaging data is needed to define the correct TMN classification. For these reasons, it cannot be used to define resectability during diagnostic iter.

At the end of 2016, AJCC was revised and the 8th edition of TNM classification was published. Some main changes were introduced in the 8th edition to better depict pCCC prognosis[3,26,27]. T4 stage is no longer linked to Bismuth-Corlette type IV pCCC, as underlined by Ebata *et al*. T4 pCCC is now defined as a tumor invading the main portal vein or its branches bilaterally, or the common hepatic artery, or unilateral second order biliary radicals with contralateral portal or hepatic artery involvement. According to the current TNM classification, N stage depends on the number of loco-regional lymph nodes involved. Furthermore, stage IIIC category was introduced in TNM staging.

Beside these changings, some comments can be pointed out: liver parenchymal invasion does not define a metastatic disease (T2b) and represent a more favorable prognostic factor than omolateral vascular invasion (T3); the main portal vein invasion (T4) is not a surgical contraindication, but requires vascular reconstruction. A proper N stage can be achieved, according to the 8th edition, only if at least 15 lymph nodes are detected on surgical specimen. A recent paper by Ruzzente *et al*[26], tried to evaluate the performance of the new TNM classification in a Western setting. Surprisingly, in this publication, the T4-staged patients had no increased risk of death compared to T1. Furthermore, the ability to predict prognosis of 8th edition N stage was not improved compared to the previous edition. These differences are probably explained by the biological behavior and surgical approach to pCCC in Western and Eastern countries[28,29].

***Microsopic morphology***

Along with the macroscopic and staging classification, pCCC can be grouped in four patterns according to its microscopic morphology[5,20]: (1) periductal infiltrating: the most common pattern, characterized by an undefined annular thickening of the duct, is frequently associated to perineural and lymphatic invasion; (2) mixed: periductal infiltrating associated with a mass forming tumor involving biliary ducts; (3) intraductal: mucosal growth associated to segmental bile duct dilatation. biliary-intrapapillary mucinosus neoplasm are included in this pattern and (4) papillary-mucinosus: this class is characterized by rich mucina secretion that clutter bile ducts. Their diagnosis is frequently associated to liver abscess.

**DIAGNOSIS**

Literature identifies the characteristics of an ideal diagnostic iter for pCCC: non-invasive imaging and characterization of pCCC, correct localization of the tumor, pre-surgical stadiation and resectability evaluation (vascular invasion and biliary spread)[30]. Once CCC is suspected, patients must be referred to specialized surgical centers to complete diagnosis and settle a correct treatment. An incorrect diagnostic pathway exposes patients to delayed diagnosis or repetition of invasive and useless examinations[31].

The onset of symptoms is not specific and most of the patients (> 65%-80%) are not resectable at the time of diagnosis[32–34]. pCCC identification can be anticipated by jaundice (90%) or cholangitis (10%). Only patients subjected to screening are found asymptomatic[5]. A diagnostic flow chart for pCCC is showed in Figure 2.

***Non-invasive diagnosis***

Ultrasound (US) is considered the first line examination. Even if it is weighted by operator-dependent sensitivity and specificity (55%-95% and 71%-96% respectively) in stenosis visualization, US offers valuable information (also using color-doppler) to establish the future diagnostic plan[35–37].

Computer tomography (CT) and magnetic resonance cholangiographic sequences (MRCP) provide complementary information. CT allows a better definition of local tumor extension, vascular invasion and metastatic disease, but only small details about intraductal extension of pCCC (sensitivity and accuracy of 60% and 92% respectively). However, the introduction of multidetector-row CT (high-resolution) has increased the ability to predict intraductal biliary spread of pCCC[38]. Bile ducts anatomy was better depict in presence of dilatated bile ducts[31].

MRCP has the best sensitivity and accuracy (92% and 76% respectively) in identifying the extension of pCCC, but alone is not enough to establish a correct surgical strategy (*e.g.,* lack in vascular invasion)[39,40]. The importance of a correct MRCP execution is highlighted in Zhang *et al*[41] review. Indeed, they demonstrated that inadequate MRCP image leads to the re-execution of the exam and up to 60% of MRCP were found incomplete or inadequate if performed in non-specialized centers.

Positron-emissions-tomography has a marginal role in pCCC staging. It can be used to identify metastatic lymph nodes, distant metastases or clarify indeterminate lesions, especially in PSC patients[42,43]. Due to its low sensitivity (< 70%), it can be considered only in selected cases: in fact, distant metastasis are better identified using CT, while EUS is the gold standard in lymphnode staging[37].

***Invasive diagnosis***

In selected pCCC cases, diagnosis should rely on invasive examinations: ERCP, percutaneous transhepatic colangiography (PTC), endoscopic ultrasound (EUS). They should be addressed to clarify the nature of a stenosis (biopsy) or to drain bile ducts[5,32,44,45], while ERCP and PTC are not more relevant than MRCP images in visualizing biliary tree[46,47]. Park *et al*[48] showed an accuracy for predicting biliary confluence and intrahepatic bile duct involvement of 91%-87% for MRCP and 85%-87% for CT combined with invasive cholangiography.

Nowadays, PTC is considered a second choice compared to ERCP due to its increased number of complications. However, Zhimin *et al*[49] described an increased accuracy of PTC (> 90%) in identifying the cranial border of pCCC (especially in pCCC with a proximal localization) compared to ERCP and MRCP.

Endoscopic ultrasound has a controversial role in pCCC diagnosis and management. It provides accurate information about localization of biliary lesions, peribilary tissue involvement, visualization of lymph nodes, hepatic vessels involvement, and it ultimately allows a proper preoperative staging[5,16,32,44,45,50]. However, EUS and EUS fine-needle-aspiration (FNA) sensitivity is reduced from distal to proximal lesions (100% and 83% respectively)[51]. Definition of N staging using EUS needs further studies: clinical trials are ongoing to identify the role of lymph nodes FNA in predicting pre-operative N stage[52].

Cytological sampling can be obtained through brushing or FNA. It is usefull in non-resectable pCCC or before surgery when diagnosis is not confirmed by non-invaisve techiniques[5,44]. EUS-FNA could also be usefull for cases with negative ERCP-examination[53]. The brushing sensitivity ranges from 20%-40%[54,55] while 79%-83% for FNA[51]. Overall specificity is 92%-100% (the number of cases performed in a hospital highly increase specificity and sensitivity)[16,56]. The low global negative predictive value of cytological sampling using ERCP, PTC and EUS does not exclude the presence of pCCC when a non-neoplastic report is given. It is worth highlighting that, although FNA or brushing allows a proper diagnosis, they are charged by an increased risk of seeding. Only small data are reported on this topic[7,52]. Seeding is a major concern especially during EUS FNA: indeed, the fine-needle crosses duodenal bulb and peritoneal cavity to sample the pCCC. For these reasons, EUS FNA must not be performed is contraindicated before liver transplantation[16,52].

A further improvement in endoscopic diagnosis is intraductal-EUS. Even if it has almost 91% accuracy[57], it has a lack in tissue sampling and a reduced radial visualization (max 2 cm). Cholangioscopy allows direct visualization of bile duct epithelium and FNA execution and has a sensitivity and specificity of 90% and 96%, and 85% and 100%, respectively[58]. Confocal laser endomicroscopy has high sensitivity, specificity and accuracy (89%-71%-82%[59]). However, many concerns are reported concerning standardization and reproducibility of this diagnostic tool, for this reason it is not suggested for a routine use[16].

***Serum markers***

Carbohydrate antigen (CA) 19-9 is elevated in 85% of pCCC, but it has a variable sensitivity (33%-93%) and specificity (67%-98%) with low positive predictive value (16%-40%). A CA 19-9 cut-off of 129 ng/dl should raise specificity at 70%[2,7,56,60–62]. The main confounding factor is jaundice: a re-evaluation after biliary decompression (BD) is suggested. Another tumor marker is CA-125, but it is seldom used outside clinical trials[7]. Immunoglobulin G4 (IgG4) are specific immunoglobulines produced during IgG4 cholangiopathy, a rare autoimmune disease associated with pancreatitis. The presence of IgG4 suggests IgG4 cholangiopathy, susceptible to steroids’ treatment rather than surgery[63]. New diagnostic approaches are based on liquid biopsy: detection of cholangiocarcinoma cell-free DNA and circulating tumor cells. Even if some authors reported a usefulness of miRNA measured in bile and blood in pCCC diagnosis, further studies are needed and it probably has a prognostic, more than a diagnostic, role[64–66].

**TO DRAIN OR NOT TO DRAIN**

BD is a key point during diagnostic and therapeutic management of the pCCC patients. A wide debate is open in literature about this topic and BD must be evaluated according to patient clinical conditions.

Diagnosis and staging in patients with a suspected pCCC are better obtained in absence of foreign bodies in biliary tree. Incorrect BD is one of the most frequent causes of delayed or miss-diagnosis, especially as regards the intraductal extension of the tumor. Hosokawa and colleagues[31] demonstrated that biliary drainage placed before proper diagnosis and staging leads to a higher rate of non-R0 resections. They hypothesized a confounding factor due to artifacts and reduction of the bile duct dilatation.

Sepsis secondary to cholangitis non-responsive to pharmacological treatment is the only absolute indication to BD. Jaundice, itching or cholangitis are not indications to drain the biliary tree during diagnostic time if the patient is a candidate for liver resection. The use of plastic stents or naso-biliary drainages is more suitable than the use of the metallic ones. Indeed the latter easily removed to obtain a correct diagnosis[11,5].

Once surgical indication is established, biliary decompression is anyway debated. Wide accordance on drainage is achieved when a two-step procedure (two-setp hepatectomy or portal vein embolization followed by hepatectomy) is needed to increase the future remnant liver (FRL) volume. Indeed, standard surgical procedure in pCCC requires the resection of a large portion of “healthy” liver parenchyma and liver hypertrophy could be needed before surgery. When a two-step procedure is programmed, whilst the risk of bacterial colonization is increased, BD can improve FRL hypertrophy[67] and could reduce morbidity and mortality[68,69]. In this setting, Eastern surgeons are more likely to use a naso-biliary drainage[31], while Western specialists prefer endoscopic stents[29].

Once a one-step hepatectomy is programmed, BD is associated to high risk of septic shock secondary to retrograde cholangitis that could exclude resectable patient from surgery[70]. In a multicenter study, Farges and colleagues[71] reported an increased mortality after BD in patients that underwent left hepatectomy (mainly due to post-operative septic shock) (adjusted OR 4.06, 95%CI 1.01 to 16.3; *P* = 0.035), while a decreased mortality rate, due to reduction of post-operative liver failure, was observed after right-side hepatectomy (adjusted OR 0.29, 95%CI: 0.11-0.77; *P* = 0.013). According to their data, the authors suggested that when a right-side hepatectomy is planned in jaundiced patients, BD should be performed and surgery scheduled whit a bilirubin < 3 mg/dL. Conversely, Celotti *et al*[72], in their meta-analyses, underlined that patients that underwent pre-operative BD had an increased rate of morbidity and wound infections with no advantages on post-operative mortality. While only a selective use of pre-operative BD is suggested (*e.g.,* patients affected by cholangitis) if one-step hepatectomy is planned, randomized prospective studies are needed to better depict the indications for BD.

BD can be achieved through percutaneous [Percutaneous Transhepatic Biliary Drainage (PTBD)] or endoscopic (plastic or metallic stent or naso-gastic tube) approach according to hospital expertise. No definitive data are published on the best technique for BD[67]. Table 2 summarizes pros and cons of the two techniques. A recent paper by Higuchi *et al*[73] estimated a comparable patient survival and morbidity in patients undergoing PTC or ERCP. While increased post-operative tumor dissemination in PTC group is reported, an increased rate of infection is highlighted in ERCP patients[74,75]. Even if some authors reported the overall superiority of PTC on ERCP[74–76], a recent randomized control[77] trial was prematurely stopped due to the higher rate of pre-surgical mortality among PTC patients (PTC *vs* ERCP: 41% *vs* 11%). Until PTBD the superiority of a technique will be demonstrated, ERCP with endoscopic stent placement should be considered the first line technique to obtain BD[78]. When curative intent resection is not feasible, ERCP must be pursued in a patient oriented approach.

**TREATMENT**

***Patient and resecability assessment***

Due to the late onset of symptoms and the aggressive nature of pCCC, less than 50% of the patients are surgically resectable at diagnosis[5]. The main criteria involved in resecability evaluation are highlighted in Table 3.

A recent paper provides a pre-operative risk score designed to predict the risk of intraoperative metastatic disease or locally advanced pCCC (*i.e.* unresectable) and the post-operative mortality[79]. Through the evaluation of 566 resected pCCC, the authors identified 5 objective criteria (bilirubin > 2 mg/dL; Bismuth classification at imaging; portal vein and hepatic artery involvement at imaging; suspicious lymph node on imaging) that allow the definition of 4 risk categories. An interesting perspective can be the adoption of this score to define the need for up-front neo-adjuvant chemotherapies in high-risk patients.

According to the complexity of surgical approach, resectability decision is strictly connected to a careful evaluation of the patient’s performance status, liver, cardiac, respiratory and kidney function[45]. Nutritional status must be evaluated before surgery and all efforts should be directed towards counterbalancing malnutrition progression. Poor nutritional condition leads to reduced survival, increased post-operative complications and prolonged hospital stay[80–82].

Advanced age was identified as one of the main changings in the characteristics of pCCC population. Despite the advanced age, the authors showed that the rate of resectable patients (70%) was similar in octogenarian and non-octogenarian patients. Post-surgical overall survival was not reduced by age even if a carefully selection of patients is needed. Indeed, 30% of octogenarians (*vs* 6% of under 60 years) were excluded to surgery for poor performance status and poor liver function[83].

***Surgical resection***

Curative approach to pCCC relies on free surgical margins. Indeed, after R0 resection, 5-year survival reaches 20%-42% in association or not with chemotherapy[8,5,45,67]. The localization of pCCC is one of the most important factors influencing surgical strategy: isolated bile duct resection is applicable in Bismuth Corlette type I pCCC, while resection of the bile duct confluence is associated to major hepatectomies in the other types. The quantity of liver parenchyma and the number of segments resected depend on the localization of the cranial border of pCCC: right hepatectomy + S4 in Bismuth-Corlette type IIIa and left hepatectomy in type IIIb. As surgical procedures (especially in type IIIa) require the resection of more than 50% of the liver, post-surgical hepatic failure must be avoided. FRL and liver functional reserve need to be carefully evaluated through liver functional tests (*e.g.,* indocyanine green clearance), imaging techniques and, if possible, liver biopsy. If the predicted FRL is less than the necessary (< 40% in hepatopatic patients, < 30% in normal liver), a single step hepatectomy is related to an increased risk of liver failure and death[84,85]. A two-step procedure (associated liver partition to portal vein ligation for staged hepatectomy or simple portal vein ligation) or pre-operative portal vein embolization (PVE) must be settled. PVE is largely adopted in the Eastern Countries (55% of the cases compared to the 7% of Western Countries)[29]. A recent study by Lee *et al*[86] developed a score to evaluate the risk of “small for size” after resection. They included in their analyses FRL, intraoperative blood loss and prothrombine time > 1.2. Olthof *et al*[69], in the same year, proposed their own score based on FRL, jaundice at presentation, preoperative cholangitis and immediate post-operative bilirubin > 2.9 mg/dL. While the authors underlined that pre-operative BD increases FRL hypertrophypost-BD cholangitis reduced the positive effect of biliary decompression on post-operative liver failure rate. Even if PVE is more frequently used in Eastern countries, the rate of post-surgical liver failure is similar to Western ones. A more aggressive approach to liver vascular pedicle, a larger lymphadenectomy and an increased rate of intraoperative trans-hepatic biliary drainage in the Eastern Countries can counterbalance the effect of PVE hypertrophy[87].

Regardless of the type of hepatectomies, resection of caudate lobe is considered the gold standard. Caudate lobe’s bile ducts open out at bile duct bifurcation and are frequently infiltrated by pCCC. Its removal increases the percentage of R0 resections (59%-87%) with better results in long-term survival (5 years survival from 33% to 44%, resection S1 *vs* non-resection HR 3.03)[88,89].

Curative surgical strategies cannot leave aside from a histological intraoperative evaluation of bile duct margins (cranial and caudal). Bile duct R0 resection is one of the most important factors influencing long-term follow-up. If neoplastic cells are detected at frozen section, surgical resection will be enlarged till feasible to obtain R0 (60% of the cases[90]). The growth of pCCC is intraluminal and the perineural spread is frequent. A resection of 1 cm above pCCC localization must be considered in the infiltrative type[91], as well as 2 cm in the papillary/mass-forming[92]. A debate in literature is open to understand the results of high-grade dysplasia detection on bile duct margins. While some studies reported comparable patients’- but reduced disease free – survival, other studies showed a reduced 2 and 5-year disease specific survival in N0 R1-high grade-dysplasia patients (2-year, 76.7% *vs* 84.3%; 5-year, 37.5% *vs* 69.3%)[73,93].

Portal vein resection can be headed if focal portal invasion (< 2 cm) of the main trunk is demonstrated. Indeed, portal vein resection does not affect post-resection outcome[4,90,94]. Conversely, hepatic artery resection is related to an increased surgical risk, without a demonstrated positive influence on long-term results[95,96].

In 2012 Neuhaus *et al*[91] proposed a new approach to liver resection in type IIIa pCCC, called “en bloc resection”. In his paper, Neuhaus presented a series of 100 type IIIa pCCC patients that received two different surgical treatements according to the tumor localization: “en bloc resection” in tumors located close to hepatic hilum (*n* = 50) and standard resection in the others (*n* = 50). “En bloc resection” consisted in right enlarged hepatectomy + S1, lymphadenectomy and en bloc resection of biliary confluence, extrahepatic bile duct, portal vein bifurcation and right hepatic artery (portal vein reconstruction is needed). 3 and 5-year survival was superior in “en bloc” group (35% and 25% *vs* 65% and 58% respectively) without an increase in surgical complications. Other authors adopted this approach with reported comparable results[97]. The “en bloc resection” is not feasible in left hepatectomy because the no touch approach on hilum is impossible, unless resection and reconstruction of the right hepatic artery are being considered.

In 2017, Kawabata *et al*[98] proposed their own surgical technique based on reduced liver manipulation and tumor spread. They described an ab-initio parenchymal transection prior to liver mobilization. Two-year survival was increased in the study group (95% *vs* 58%) with a decrease in surgical complications.

Bismuth-Corlette Type IV pCCC deserves a peculiar consideration (Table 4). It was considered a surgical contraindication for several years due to the bilateral bile duct invasion. However, in the last few years, the surgical approach to this type of pCCC changed due to the Japanese group’s contributions. In 2018, they published[99] a series of 216 patients with Bismuth Corlette type IV pCCC that underwent surgical resection: R0 resection was achieved in 76.2% of the cases, post-surgical morbidity was 41.6% and the 5-year survival was superior in the resected patients (32.8% *vs* 1.5%). Even if the resection of type IV pCCC is feasible and the results are promising, two main concerns are emerging: an undiagnosed vascular invasion often detected at histopathological evaluation and the high rate of N positive specimens[100,101]. The adoption of an en-bloc approach can be suggested in this type of pCCC to avoid unexpected vascular invasion diagnosis. Furthermore, neoadjuvant chemotherapy can be useful in type IV pCCC to select chemo-responsive tumors, reduce the possible futile resections and improve the extent of R0 rate.

***Liver transplantation***

In unresectable pCCC, liver transplantation (LT) can be considered within research protocols and with strict inclusion criteria[102]. These criteria are: tumor smaller than 3 cm, no evidence of lymph node involvement or metastatic disease, and no prior percutaneous or endoscopic biopsy[103]. The initial results of LT for pCCC were poor. Indeed, overall survival (OS) following LT alone for incidentally diagnosed pCCC in PSC are < 40% at 3-year[104]. LT for pCCC gained new enthusiasm with the publication of Mayo Clinic results: in their studies they identified the risks for disease progression and recurrence, and a multimodal therapy (neoadjuvant chemoradiation therapy is mandatory prior to listing) was successfully applied. In the published series of LT performed at Mayo Clinic, the LT group with neoadjuvant chemoradiation (38 patients) achieved better 1 year (92% *vs* 82%), 3 years (82% *vs* 48%), and 5 years (82% *vs* 21%) overall survival (OS) when compared with the resection group (26 patients). Consistently, the LT group experienced lower post-transplant recurrence (13% *vs* 27%)[105]. Ethun *et al*[106] compared 191 patients that underwent curative resection with 41 patients that received LT (with Mayo Clinic Protocl) for pCCC. In LT group, 38% of the patients were excluded. Patients who underwent transplant for pCCC showed improved OS compared with resection (5-year: 64% *vs* 18%; *P* < 0.001). The same results were obtained if patients with tumors < 3 cm with lymph-node negative disease and without PSC patients from resection group (5-year: 54% *vs* 29%; *P* = 0.03).

Resective surgery in pCCC is the standard of care for suitable patients outside the setting of PSC[107]. To date, even if there are no randomized controlled trials, LT after aggressive neoadjuvant therapy (including external beam and transluminal radiation, as well as systemic chemotherapy) seems like an adequate treatment for both unresectable pCCC, as well as pCCC arising in the setting of PSC[108].

***Laparoscopic exploration***

The role of laparoscopic exploration (LE) decreased over time together with the increase of sensibility and specificity of imaging techniques. Routine LE is not recommended, but it can be useful in T2/T3 pCCC according to AJCC classification or type III and IV according to Bismuth-Corlette[92,109]. LE is the only way to detect peritoneal metastasis prior to laparotomy, due to the low predictive value of non-invasive technique. Furthermore, routine opening of the lesser sac during LE can help in detecting metastatic lymphnode of hepatic artery (N2 stage)[110]. A recent meta-analysis[111] collected 8 studies evaluating the role of LE: 32.4% of the patients were found unresectable at exploration with a sensitivity of 56% and a specificity of 100%. In another study, sensitivity of LE increased from 24% to 41% using intraoperative ultrasound[112].

***Lymphadenectomy***

Lymphadenectomy is an essential part of the surgical intervention, as well as bile duct and liver resection. In pCCC, hilar, hepatic artery, portal vein, bile duct, celiac trunk and retroduodenal lymph nodes must be resected. The role of lymphadenectomy is to obtain an adequate post-surgical staging, even if some authors reported a survival benefit[88,113,114]. The 8th edition of TNM classification identifies 15 lymph nodes as the minimum number to obtain an adequate N staging (N1 when 1 to 3 regional lymph nodes are positive, N2 when more than 4 regional lymph nodes are positive)[4]. Regional lymph nodes are located in the hepatic hilum and in the hepatoduodenal ligament (pericholedochal nodes). The first systematic review on lymphadenectomy was published in 2015[115]. Beside AJCC classification, Kambakamba *et al*[115] rose criticism about the minimum number of dissected nodes. Indeed, in their review, only 9% of the series reported a number of dissected lymph nodes > 15, while N positivity ranged from 31% to 58%[116,117]. Their analyses showed that 7 is the number of lymph nodes that ensures the highest detection rate of N1 and the lowest rate of potentially understated N0 patients. The impact on survival of extended lymphadenectomy (>15 lymph nodes) is debated, because it does not improve 5-year survival and median OS with an increased rate of surgical complications[5]. The presence of malignant cells within dissected lymph nodes (N1) has a detrimental impact on patient survival: 3-year survival 35% *vs* 10% in N0 *vs* N1 patients[115]. It was recently suggested that the presence of a small number of metastatic lymph nodes (lymph nodal ratio < 0.2 or number of lymph node < 4) does not exclude good long-term survival[114,118].

***Chemotherapy, radiotherapy and palliative treatments***

The role of neo-adjuvant chemotherapy in pCCC is not clearly identified and it is mostly adopted in clinical studies.

The Mayo Clinic protocol combined neoadjuvant chemosensitization with 5-fluorouracil, external beam radiotherapy plus brachytherapy boost and orthotopic liver transplantation for patients with stage I and II pCCC. In a retrospective series, thirty-eight patients underwent liver transplantation while 54 patients were explored for resection. Patients receiving transplantation had better one-, three- and five-year survival (92%, 82% and 82%) compared to resection (82%, 48% and 21%, *P* = 0.022). Transplanted patients had fewer recurrences compared to resection (13% *vs* 27%)[105]. The ongoing phase III TRANSPHIL trial is comparing resection with neoadjuvant chemoradiotherapy capecitabine-based and orthotopic liver transplantation[102].

Resected patients, except the R0 pT1N0M0 ones, as well as non-resected patients must undertake chemotherapy with adjuvant intent. The role of adjuvant chemoradiotherapy is not well defined due to the lack of data from randomized trial[8]. On the contrary, the phase III randomized BILCAP trial, comparing adjuvant capecitabine with observation in resected biliary tract cancers, showed an increased OS for the experimental arm in the protocol-specified sensitivity analysis (adjusting for minimisation factors, nodal status, grade and gender). Specifically, median OS in the capecitabine arm was 53 mo *vs* 36 mo in the observation group (*P* = 0.028)[119]. Diversely, the phase III Prodige 12-Accord 18 trial, comparing chemotherapy with oxaliplatin and gemcitabine *vs* observation after resection, failed to show an increase in OS (*P* = 0.74)[120].

A further phase III study, comparing cisplatin and gemcitabine treatment *vs* observation (ACTICCA-1) is open and recruiting patients[121].

A meta-analysis evaluating studies of adjuvant chemotherapy, chemoradiotherapy or radiotherapy in biliary tract cancers found a nonsignificant improvement in OS compared with adjuvant treatment compared with surgery alone (*P* = 0.06). However, patients treated with chemoradiotherapy (OR 0.61) or chemotherapy (OR 0.39) had greater benefit with compared to radiotherapy alone (OR 0.98, *P* = 0.02) and, specifically, the greatest benefit was in those patients with nodes positive (OR 0.49, *P* = 0.004) and R1 disease (OR 0.36, *P* = 0.002)[122]. Another meta-analysis of randomized and non-randomized studies confirmed the improvement in OS given by adjuvant chemotherapy, with a 41% of risk of death reduction compared with observation after resection (HR 0.59, *P* < 0.0001)[123]. In contrast, a meta-analysis of randomized clinical trials showed no effect of adjuvant treatment on OS improvement (HR 0.91) and a mild improvement in recurrence-free survival (HR 0.83). Neither the lymph-node positive (HR 0.84) nor the surgical margin positive subgroups (HR 0.95) had an OS prolongation with adjuvant treatment[124]. Nassour *et al*[125] retrospectively analyzed the National Cancer Database to evaluate the role of adjuvant chemotherapy (AT) on pCCC. They found the patients that received AT were younger, with a higher pathological T and N staging, a higher rate of non-R0 resections and a longer hospital stay than patients that did not undergo AT. After a propensity match analyses, they found that AT had a beneficial role on 5-year survival in all resected patients, especially in high risk (non-R0 resection) ones. Furthermore, an advantage on 5-year survival was showed for patient that underwent chemo-radiotherapy compared to chemotherapy alone.

In case of locally-advanced unresectable disease, the role of radiation therapy remains unclear[8]. A phase II trial compared gemcitabine plus oxaliplatin *vs* chemoradiotherapy with 5-fluorouracil and cisplatin. The trial closed before completion due to slow recruitment, showing an increased median OS (19.9 mo *vs* 13.5 mo, HR 0.69) and progression free survival (11.0 mo *vs* 5.8 mo, HR 0.65) for the chemotherapy arm[126]. A small series using image-guided intensity-modulated radiation therapy both in gallbladder and extrahepatic bile ducts cancers demonstrated the feasibility of the procedure, allowing safe dose escalation[127].

Exclusive chemotherapy remains a suitable option in case of unresectable disease. The phase III UK ABC-02 study has established the cisplatin/gemcitabine chemotherapy as the new standard of care in patients with advanced biliary tract cancer. Median survival was 11.7 for the combination therapy compared with 8.1 mo for the gemcitabine only comparator arm (*P* < 0.001)[128]. The benefit of the combination was present independent of age (inferior *vs* superior to 65 years), gender, primary tumour site (intra *vs* extrahepatic *vs* gallbladder *vs* ampullary), stage of disease (locally advanced *vs* metastatic) and previous therapy (surgery *vs* stenting)[129]. In case of altered renal function, oxaliplatin may be used instead of cisplatin, while in case of poorer clinical conditions, gemcitabine monotherapy may be a choice[8].

Beyond failure of first line treatment, evidence is scarce. A recent systematic review of the literature gathering 25 non-randomized prospective and retrospective studies reported a median progression-free survival (mPFS) and median overall-survival (mOS) of 3.2 and 7.2 mo, respectively[130]. A large multicenter Italian survey and pooled analysis with published data found a mPFS of 3.1 and median OS of 6.3 mo[131]. Recently, the results of a phase III trial (ABC-06) comparing modified FOLFOX to best supportive care found an advantage in mOS (6.2 mo *vs* 5.3 mo) with adjusted hazard ratio (HR) 0.69. Patients treated with FOLFOX had a prolongation of median radiological PFS or 4 mo. Moreover, the study showed a 1% rate of complete responses, 4% of partial responses and a 28% of cases had disease stabilization. The overall disease control rate was 33%. Due to the results of this trial, modified FOLFOX should be considered the standard of care in the second-line treatment of BTCs[132].

Isocitrate dehydrogenase isoenzyme 1 (IDH1) mutations are present in 15% of patients with CCC. Recently, the results of treatment with ivosedinib, an oral small-molecule inhibitor of mutant IDH1 (mIDH1), have been presented. In patients with mIDH1 progressed to first line treatment, mPFS was 2.7 mo with ivosedinib *vs* 1.4 mo for placebo (HR 0.37, *P* < 0.001). MOS was 10.8 mo for ivosedinib *vs* 9.7 mo for placebo (10.8 mo *vs* 9.7 mo for placebo, HR 0.69, *P* = 0.06). However, mOS for placebo decreased to 6 mo after considering a 57% crossover-rate from placebo to experimental treatment and the difference in mOS between ivosedinib and placebo became statistically significant (HR 0.46, *P* = 0.0008)[133]. Ivosedinib is the first targeted molecular agent showing efficacy in the treatment of advanced CCC and its use will probably become a standard in the second-line treatment of mIDH1 CCC.

In patients with an estimated survival longer than 3 mo, bile duct decompression should be reached. Percutaneous or endoscopic approaches are both possibile. ERCP has the advantage of a totally internal stent, without the discomfort of PTBD (less pain and aesthetic impact). On the other hand, endoscopic stents are not easy to arrange in type III and IV pCCC. Percutaneous transhepatic biliary stent placement is an effective alternative to endoscopic stent to relieve cholestasis77. Combined seed intracavitary irradiation with 125I can be applied to obtain a better stent patency and survival[134,135].

**OUTCOME AND RESULTS**

Survival after pCCC diagnosis is poor and frequently accompanied by a prolonged hospitalization and a wide use of diagnostic and therapeutic techniques. Median survival is 12 mo in patients not susceptible to surgery and 38 (range 25-40) mo in radically resected patients. Koerkamp and colleagues in 2015[136] evaluated a population of 306 patients that underwent surgical resection for pCCC: overall 5-year survival was 35%, while it increased to 50% in the 122 (42%) patients N0R0 resection. Excluding R2 patients and patients with intra-hospital death, the median time to recurrence was 31 mo with a 3-year survival after recurrence of 18%. Eastern post-operative survival is slightly better that Western one (median OS of 56 mo *vs* 43 mo respectively, *P* = 0.028), depicting a possible more aggressive behavior of pCCC in Western world[29].

In literature, many variables influence 3 and 5-year survival: resection margins, type of resection, T stage, N stage, staging, lymphovascular invasion and caudate lobe invasion[88,137,138]. T stage and N positivity are burdened by the highest Hazard Ratios: N1 HR 2.32 (5-year survival N1 *vs* N0 11% *vs* 35%) and T3-4 HR 1.86 (5-year survival T1-2 *vs* T3-4 47% *vs* 19%)[137]. R0 resection was recently underlined as the main factor influencing the outcome, irrespective of the tumor staging[31,139]. Three and five-year recurrence-free survival was 57% and 49% in R0 resection, while 31% and 16% in R1 resection. In stage I, II and III, R0 resection was directly related to segment 1 resection and age > 56 year[31]. Lymphovascular invasion was identified as one of the detrimental prognostic factors on patient and disease free survival. Its role was investigated in lymph nodes of positive and negative patients and in both was identified as a detrimental factor[138]. Furthermore, lymphovascular invasion resulted in an increased percentage of patients with lymph nodes metastasis, but not with a decrease in R0 rate, also in Bismuth-Corlette tipe IV pCCC[101,137,140].

In 2017, van Vugt *et al*[95] evaluated the impact of vascular invasion on 674 patients affected by pCCC. Median OS was considered independently from curative resection. They found that any hepatic artery involvement is related to poor prognosis (median OS: 16.9 (13.2-20.5) mo *vs* 10.3 (8.9-11.7) mo, *P* < 0.001), while unilateral or main portal vein involvement was not related to reduced median OS [14.7 (11.7-17.6) mo *vs* 13.3 (11.0-15.7) mo, *P* = 0.116]. This paper confirmed the results provided by other authors and highlighted the necessity of a further modification of the 8th AJCC classification. Indeed, the T4 classification does not discriminate arterial or main portal vein infiltration with a reduced ability to predict patient outcome[26].

The resection benefits have to deal with the high surgical morbidity and mortality of pCCC. In both Western and Eastern Centre, 90-d surgical mortality ranges around 10%.

The 5-year survival rate for perihilar cholangiocarcinoma in patients receiving a liver transplant is greater than 70%[105], although these data are affected by selection bias. A number of factors were identified as predictors of outcomes in pCCC liver transplantation: elevated CA 19-9, portal vein encasement, perineural invasion and absence of vital tumor at explant histopathological examination[140–142]. Recent evidence showed that overall survival is affected by the amount of necrotic tumor after neo-adjuvant therapy (patients with minimal response were 9.0 times more likely to die than patients with a complete tumor necrosis) and by lymphovascular invasion[140].

**CONCLUSION**

In conclusion, perihilar cholangiocarcinoma is characterized by high mortality and low rate of resectable patients. The main issue for surgeons is to obtain the most rapid and accurate diagnosis. For this reason, patients must be referred to specialized centers after a suspect diagnosis. Biliary drainage is an important tool in non-resectable patients and in those that are candidate to two-stage hepatectomy. It must be obtained after a definitive diagnosis. Even if surgery represents the only curative option, it is still charged by reduced long-term survival.

**ACKNOWLEDGEMENTS**

Authors would like to thank “Associazione Italiana Copev per la prevenzione e cura dell'epatite virale Beatrice Vitiello- ONLUS” for the valuable support and Erica Bosco for langue review.

**REFERENCES**

1 **Doherty B**, Nambudiri VE, Palmer WC. Update on the Diagnosis and Treatment of Cholangiocarcinoma. *Curr Gastroenterol Rep* 2017; **19**: 2 [PMID: 28110453 DOI: 10.1007/s11894-017-0542-4]

2 **Kondo S**, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, Furuse J, Saito H, Tsuyuguchi T, Yamamoto M, Kayahara M, Kimura F, Yoshitomi H, Nozawa S, Yoshida M, Wada K, Hirano S, Amano H, Miura F; Japanese Association of Biliary Surgery; Japanese Society of Hepato-Biliary-Pancreatic Surgery; Japan Society of Clinical Oncology. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. *J Hepatobiliary Pancreat Surg* 2008; **15**: 41-54 [PMID: 18274843 DOI: 10.1007/s00534-007-1279-5]

3 **Meng ZW**, Pan W, Hong HJ, Chen JZ, Chen YL. Macroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC/UICC TNM staging system. *Oncotarget* 2017; **8**: 101165-101174 [PMID: 29254154 DOI: 10.18632/oncotarget.20932]

4 **Brierley JD**, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours, 8th Edition. John Wiley & Sons, 2017. Available from: <https://play.google.com/store/books/details?id=642GDQAAQBAJ>

5 **AI** **di Oncologia Medica**. Linee guida TUMORI DELLE VIE BILIARI. Available from: <http://media.aiom.it/userfiles/files/doc/LG/2016_LG_AIOM_Vie_biliari.pdf>

6 **Bergquist A**, von Seth E. Epidemiology of cholangiocarcinoma. *Best Pract Res Clin Gastroenterol* 2015; **29**: 221-232 [PMID: 25966423 DOI: 10.1016/j.bpg.2015.02.003]

7 **Khan SA**, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. *Gut* 2012; **61**: 1657-1669 [PMID: 22895392 DOI: 10.1136/gutjnl-2011-301748]

8 **Valle JW**, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D; ESMO Guidelines Committee. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2016; **27**: v28-v37 [PMID: 27664259 DOI: 10.1093/annonc/mdw324]

9 **AI** **di Oncologia Medica.** I Numeri del Cancro in Italia. [accessed 2019 March 5]. Associazione Italiana dei Registri Tumori, Istituto Superiore di Sanità. Available from: [https://www.aiom.it/wp-content/uploads/2018/10/2018\_ NumeriCancro-operatori.pdf](https://www.aiom.it/wp-content/uploads/2018/10/2018_%20NumeriCancro-operatori.pdf)

10 **Deoliveira ML**, Schulick RD, Nimura Y, Rosen C, Gores G, Neuhaus P, Clavien PA. New staging system and a registry for perihilar cholangiocarcinoma. *Hepatology* 2011; **53**: 1363-1371 [PMID: 21480336 DOI: 10.1002/hep.24227]

11 **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. *J Hepatol* 2009; **51**: 237-267 [PMID: 19501929 DOI: 10.1016/j.jhep.2009.04.009]

12 **Sierra H**, Cordova M, Chen CJ, Rajadhyaksha M. Confocal imaging-guided laser ablation of basal cell carcinomas: an ex vivo study. *J Invest Dermatol* 2015; **135**: 612-615 [PMID: 25178106 DOI: 10.1038/jid.2014.371]

13 **Jarnagin W**, Winston C. Hilar cholangiocarcinoma: diagnosis and staging. *HPB (Oxford)* 2005; **7**: 244-251 [PMID: 18333200 DOI: 10.1080/13651820500372533]

14 **Blechacz B**, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. *Hepatology* 2008; **48**: 308-321 [PMID: 18536057 DOI: 10.1002/hep.22310]

15 **Sierra H**, Cordova M, Chen CJ, Rajadhyaksha M. Confocal imaging-guided laser ablation of basal cell carcinomas: an ex vivo study. *J Invest Dermatol* 2015; **135**: 612-615 [PMID: 25178106 DOI: 10.1038/jid.2014.371]

16 **Rizvi S**, Eaton J, Yang JD, Chandrasekhara V, Gores GJ. Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma. *Semin Liver Dis* 2018; **38**: 160-169 [PMID: 29871021 DOI: 10.1055/s-0038-1655775]

17 **Sripa B**, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. *Curr Opin Gastroenterol* 2008; **24**: 349-356 [PMID: 18408464 DOI: 10.1097/MOG.0b013e3282fbf9b3]

18 **Tabibian JH**, O'Hara SP, Splinter PL, Trussoni CE, LaRusso NF. Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis. *Hepatology* 2014; **59**: 2263-2275 [PMID: 24390753 DOI: 10.1002/hep.26993]

19 **Chung BK**, Karlsen TH, Folseraas T. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma. *Biochim Biophys Acta Mol Basis Dis* 2018; **1864**: 1390-1400 [PMID: 28844951 DOI: 10.1016/j.bbadis.2017.08.020]

20 **Lendvai G**, Szekerczés T, Illyés I, Dóra R, Kontsek E, Gógl A, Kiss A, Werling K, Kovalszky I, Schaff Z, Borka K. Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis. *Pathol Oncol Res* 2020; **26**: 3-15 [PMID: 30448973 DOI: 10.1007/s12253-018-0491-8]

21 **Sia D**, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia-Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. *Gastroenterology* 2013; **144**: 829-840 [PMID: 23295441 DOI: 10.1053/j.gastro.2013.01.001]

22 **Marino D**, Leone F, Cavalloni G, Cagnazzo C, Aglietta M. Biliary tract carcinomas: from chemotherapy to targeted therapy. *Crit Rev Oncol Hematol* 2013; **85**: 136-148 [PMID: 22809696 DOI: 10.1016/j.critrevonc.2012.06.006]

23 **Paul A**, Kaiser GM, Molmenti EP, Schroeder T, Vernadakis S, Oezcelik A, Baba HA, Cicinnati VR, Sotiropoulos GC. Klatskin tumors and the accuracy of the Bismuth-Corlette classification. *Am Surg* 2011; **77**: 1695-1699 [PMID: 22273233]

24 **Zervos EE**, Osborne D, Goldin SB, Villadolid DV, Thometz DP, Durkin A, Carey LC, Rosemurgy AS. Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. *Am J Surg* 2005; **190**: 810-815 [PMID: 16226963 DOI: 10.1016/j.amjsurg.2005.07.025]

25 **Park J**, Kim MH, Kim KP, Park DH, Moon SH, Song TJ, Eum J, Lee SS, Seo DW, Lee SK. Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study. *Gut Liver* 2009; **3**: 298-305 [PMID: 20431764 DOI: 10.5009/gnl.2009.3.4.298]

26 **Ruzzenente A**, Bagante F, Ardito F, Campagnaro T, Scoleri I, Conci S, Iacono C, Giuliante F, Guglielmi A. Comparison of the 7th and 8th editions of the American Joint Committee on Cancer Staging Systems for perihilar cholangiocarcinoma. *Surgery* 2018; **164**: 244-250 [PMID: 29801730 DOI: 10.1016/j.surg.2018.03.012]

27 **Ebata T**, Kosuge T, Hirano S, Unno M, Yamamoto M, Miyazaki M, Kokudo N, Miyagawa S, Takada T, Nagino M. Proposal to modify the International Union Against Cancer staging system for perihilar cholangiocarcinomas. *Br J Surg* 2014; **101**: 79-88 [PMID: 24375300 DOI: 10.1002/bjs.9379]

28 **Young AL**, Prasad KR, Toogood GJ, Lodge JP. Surgical treatment of hilar cholangiocarcinoma in a new era: comparison among leading Eastern and Western centers, Leeds. *J Hepatobiliary Pancreat Sci* 2010; **17**: 497-504 [PMID: 19859651 DOI: 10.1007/s00534-009-0203-6]

29 **Olthof PB**, Miyasaka M, Koerkamp BG, Wiggers JK, Jarnagin WR, Noji T, Hirano S, van Gulik TM. A comparison of treatment and outcomes of perihilar cholangiocarcinoma between Eastern and Western centers. *HPB (Oxford)* 2019; **21**: 345-351 [PMID: 30087051 DOI: 10.1016/j.hpb.2018.07.014]

30 **Sainani NI**, Catalano OA, Holalkere NS, Zhu AX, Hahn PF, Sahani DV. Cholangiocarcinoma: current and novel imaging techniques. *Radiographics* 2008; **28**: 1263-1287 [PMID: 18794305 DOI: 10.1148/rg.285075183]

31 **Hosokawa I**, Shimizu H, Yoshitomi H, Furukawa K, Takayashiki T, Miyazaki M, Ohtsuka M. Impact of Biliary Drainage on Multidetector-Row Computed Tomography on R0 Resection of Perihilar Cholangiocarcinoma. *World J Surg* 2018; **42**: 3676-3684 [PMID: 29752510 DOI: 10.1007/s00268-018-4654-2]

32 **Brandi G**, Venturi M, Pantaleo MA, Ercolani G; GICO. Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long-standing experience of a referral center. *Dig Liver Dis* 2016; **48**: 231-241 [PMID: 26769568 DOI: 10.1016/j.dld.2015.11.017]

33 **Regimbeau JM**, Fuks D, Le Treut YP, Bachellier P, Belghiti J, Boudjema K, Baulieux J, Pruvot FR, Cherqui D, Farges O; AFC-HC study group. Surgery for hilar cholangiocarcinoma: a multi-institutional update on practice and outcome by the AFC-HC study group. *J Gastrointest Surg* 2011; **15**: 480-488 [PMID: 21249527 DOI: 10.1007/s11605-011-1414-0]

34 **Nagino M**. Surgical Treatment of Perihilar Cholangiocarcinoma: Resection or Transplant? *Ann Surg* 2018; **267**: 806-807 [PMID: 29206670 DOI: 10.1097/SLA.0000000000002624]

35 **Bloom CM**, Langer B, Wilson SR. Role of US in the detection, characterization, and staging of cholangiocarcinoma. *Radiographics* 1999; **19**: 1199-1218 [PMID: 10489176 DOI: 10.1148/radiographics.19.5.g99se081199]

36 **Chung YE**, Kim MJ, Park YN, Choi JY, Pyo JY, Kim YC, Cho HJ, Kim KA, Choi SY. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. *Radiographics* 2009; **29**: 683-700 [PMID: 19448110 DOI: 10.1148/rg.293085729]

37 **Joo I**, Lee JM, Yoon JH. Imaging Diagnosis of Intrahepatic and Perihilar Cholangiocarcinoma: Recent Advances and Challenges. *Radiology* 2018; **288**: 7-13 [PMID: 29869969 DOI: 10.1148/radiol.2018171187]

38 **Senda Y**, Nishio H, Oda K, Yokoyama Y, Ebata T, Igami T, Sugiura T, Shimoyama Y, Nimura Y, Nagino M. Value of multidetector row CT in the assessment of longitudinal extension of cholangiocarcinoma: correlation between MDCT and microscopic findings. *World J Surg* 2009; **33**: 1459-1467 [PMID: 19381719 DOI: 10.1007/s00268-009-0025-3]

39 **Masselli G**, Manfredi R, Vecchioli A, Gualdi G. MR imaging and MR cholangiopancreatography in the preoperative evaluation of hilar cholangiocarcinoma: correlation with surgical and pathologic findings. *Eur Radiol* 2008; **18**: 2213-2221 [PMID: 18463877 DOI: 10.1007/s00330-008-1004-z]

40 **Sun HY**, Lee JM, Park HS, Yoon JH, Baek JH, Han JK, Choi BI. Gadoxetic acid-enhanced MRI with MR cholangiography for the preoperative evaluation of bile duct cancer. *J Magn Reson Imaging* 2013; **38**: 138-147 [PMID: 23281093 DOI: 10.1002/jmri.23957]

41 **Zhang H**, Zhu J, Ke F, Weng M, Wu X, Li M, Quan Z, Liu Y, Zhang Y, Gong W. Radiological Imaging for Assessing the Respectability of Hilar Cholangiocarcinoma: A Systematic Review and Meta-Analysis. *Biomed Res Int* 2015; **2015**: 497942 [PMID: 26448940 DOI: 10.1155/2015/497942]

42 **Naser B**. [Removable dentures for children]. *Cah Prothese* 1991; **76**: 20-26 [PMID: 1817745 DOI: 10.1111/j.1572-0241.2007.01710.x]

43 **Jiang L**, Tan H, Panje CM, Yu H, Xiu Y, Shi H. Role of 18F-FDG PET/CT Imaging in Intrahepatic Cholangiocarcinoma. *Clin Nucl Med* 2016; **41**: 1-7 [PMID: 26402131 DOI: 10.1097/RLU.0000000000000998]

44 **Miyazaki M**, Yoshitomi H, Miyakawa S, Uesaka K, Unno M, Endo I, Ota T, Ohtsuka M, Kinoshita H, Shimada K, Shimizu H, Tabata M, Chijiiwa K, Nagino M, Hirano S, Wakai T, Wada K, Isayama H, Okusaka T, Tsuyuguchi T, Fujita N, Furuse J, Yamao K, Murakami K, Yamazaki H, Kijima H, Nakanuma Y, Yoshida M, Takayashiki T, Takada T. Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition. *J Hepatobiliary Pancreat Sci* 2015; **22**: 249-273 [PMID: 25787274 DOI: 10.1002/jhbp.233]

45 **Ruzzenente A**, Fassan M, Conci S, Simbolo M, Lawlor RT, Pedrazzani C, Capelli P, D'Onofrio M, Iacono C, Scarpa A, Guglielmi A. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients. *Ann Surg Oncol* 2016; **23**: 1699-1707 [PMID: 26717940 DOI: 10.1245/s10434-015-5046-6]

46 **Vogl TJ**, Schwarz WO, Heller M, Herzog C, Zangos S, Hintze RE, Neuhaus P, Hammerstingl RM. Staging of Klatskin tumours (hilar cholangiocarcinomas): comparison of MR cholangiography, MR imaging, and endoscopic retrograde cholangiography. *Eur Radiol* 2006; **16**: 2317-2325 [PMID: 16622690 DOI: 10.1007/s00330-005-0139-4]

47 **Jorgensen JE**, Waljee AK, Volk ML, Sonnenday CJ, Elta GH, Al-Hawary MM, Singal AG, Taylor JR, Elmunzer BJ. Is MRCP equivalent to ERCP for diagnosing biliary obstruction in orthotopic liver transplant recipients? A meta-analysis. *Gastrointest Endosc* 2011; **73**: 955-962 [PMID: 21316670 DOI: 10.1016/j.gie.2010.12.014]

48 **Park HS**, Lee JM, Choi JY, Lee MW, Kim HJ, Han JK, Choi BI. Preoperative evaluation of bile duct cancer: MRI combined with MR cholangiopancreatography versus MDCT with direct cholangiography. *AJR Am J Roentgenol* 2008; **190**: 396-405 [PMID: 18212225 DOI: 10.2214/AJR.07.2310]

49 **Zhimin G**, Noor H, Jian-Bo Z, Lin W, Jha RK. Advances in diagnosis and treatment of hilar cholangiocarcinoma -- a review. *Med Sci Monit* 2013; **19**: 648-656 [PMID: 23921971 DOI: 10.12659/MSM.889379]

50 **Song J**, Li Y, Bowlus CL, Yang G, Leung PSC, Gershwin ME. Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review. *Clin Rev Allergy Immunol* 2020; **58**: 134-149 [PMID: 31463807 DOI: 10.1007/s12016-019-08764-7]

51 **Mohamadnejad M**, DeWitt JM, Sherman S, LeBlanc JK, Pitt HA, House MG, Jones KJ, Fogel EL, McHenry L, Watkins JL, Cote GA, Lehman GA, Al-Haddad MA. Role of EUS for preoperative evaluation of cholangiocarcinoma: a large single-center experience. *Gastrointest Endosc* 2011; **73**: 71-78 [PMID: 21067747 DOI: 10.1016/j.gie.2010.08.050]

52 **Levy MJ**, Heimbach JK, Gores GJ. Endoscopic ultrasound staging of cholangiocarcinoma. *Curr Opin Gastroenterol* 2012; **28**: 244-252 [PMID: 22274618 DOI: 10.1097/MOG.0b013e32835005bc]

53 **Ohshima Y**, Yasuda I, Kawakami H, Kuwatani M, Mukai T, Iwashita T, Doi S, Nakashima M, Hirose Y, Asaka M, Moriwaki H. EUS-FNA for suspected malignant biliary strictures after negative endoscopic transpapillary brush cytology and forceps biopsy. *J Gastroenterol* 2011; **46**: 921-928 [PMID: 21526370 DOI: 10.1007/s00535-011-0404-z]

54 **Barr Fritcher EG**, Voss JS, Brankley SM, Campion MB, Jenkins SM, Keeney ME, Henry MR, Kerr SM, Chaiteerakij R, Pestova EV, Clayton AC, Zhang J, Roberts LR, Gores GJ, Halling KC, Kipp BR. An Optimized Set of Fluorescence In Situ Hybridization Probes for Detection of Pancreatobiliary Tract Cancer in Cytology Brush Samples. *Gastroenterology* 2015; **149**: 1813-1824.e1 [PMID: 26327129 DOI: 10.1053/j.gastro.2015.08.046]

55 **Trikudanathan G**, Navaneethan U, Njei B, Vargo JJ, Parsi MA. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. *Gastrointest Endosc* 2014; **79**: 783-789 [PMID: 24140129 DOI: 10.1016/j.gie.2013.09.015]

56 **Rizvi S**, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. *Nat Rev Clin Oncol* 2018; **15**: 95-111 [PMID: 28994423 DOI: 10.1038/nrclinonc.2017.157]

57 **Meister T**, Heinzow HS, Woestmeyer C, Lenz P, Menzel J, Kucharzik T, Domschke W, Domagk D. Intraductal ultrasound substantiates diagnostics of bile duct strictures of uncertain etiology. *World J Gastroenterol* 2013; **19**: 874-881 [PMID: 23430958 DOI: 10.3748/wjg.v19.i6.874]

58 **Navaneethan U**, Hasan MK, Kommaraju K, Zhu X, Hebert-Magee S, Hawes RH, Vargo JJ, Varadarajulu S, Parsi MA. Digital, single-operator cholangiopancreatoscopy in the diagnosis and management of pancreatobiliary disorders: a multicenter clinical experience (with video). *Gastrointest Endosc* 2016; **84**: 649-655 [PMID: 26995690 DOI: 10.1016/j.gie.2016.03.789]

59 **Slivka A**, Gan I, Jamidar P, Costamagna G, Cesaro P, Giovannini M, Caillol F, Kahaleh M. Validation of the diagnostic accuracy of probe-based confocal laser endomicroscopy for the characterization of indeterminate biliary strictures: results of a prospective multicenter international study. *Gastrointest Endosc* 2015; **81**: 282-290 [PMID: 25616752 DOI: 10.1016/j.gie.2014.10.009]

60 **Viterbo D**, Gausman V, Gonda T. Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy. *World J Gastrointest Endosc* 2016; **8**: 128-142 [PMID: 26862363 DOI: 10.4253/wjge.v8.i3.128]

61 **Kondo N**, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Sasaki H, Sueda T. Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma. *J Surg Oncol* 2014; **110**: 422-429 [PMID: 24889968 DOI: 10.1002/jso.23666]

62 **Charatcharoenwitthaya P**, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. *Hepatology* 2008; **48**: 1106-1117 [PMID: 18785620 DOI: 10.1002/hep.22441]

63 **Oseini AM**, Chaiteerakij R, Shire AM, Ghazale A, Kaiya J, Moser CD, Aderca I, Mettler TA, Therneau TM, Zhang L, Takahashi N, Chari ST, Roberts LR. Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. *Hepatology* 2011; **54**: 940-948 [PMID: 21674559 DOI: 10.1002/hep.24487]

64 **Nakaoka T**, Saito Y, Saito H. Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma. *Int J Mol Sci* 2017; **18**: 1111 [PMID: 28545228 DOI: 10.3390/ijms18061111]

65 **Ghidini M**, Pizzo C, Botticelli A, Hahne JC, Passalacqua R, Tomasello G, Petrelli F. Biliary tract cancer: current challenges and future prospects. *Cancer Manag Res* 2019; **11**: 379-388 [PMID: 30643463 DOI: 10.2147/CMAR.S157156]

66 **Li L**, Masica D, Ishida M, Tomuleasa C, Umegaki S, Kalloo AN, Georgiades C, Singh VK, Khashab M, Amateau S, Li Z, Okolo P, Lennon AM, Saxena P, Geschwind JF, Schlachter T, Hong K, Pawlik TM, Canto M, Law J, Sharaiha R, Weiss CR, Thuluvath P, Goggins M, Shin EJ, Peng H, Kumbhari V, Hutfless S, Zhou L, Mezey E, Meltzer SJ, Karchin R, Selaru FM. Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. *Hepatology* 2014; **60**: 896-907 [PMID: 24497320 DOI: 10.1002/hep.27050]

67 **Rassam F**, Roos E, van Lienden KP, van Hooft JE, Klümpen HJ, van Tienhoven G, Bennink RJ, Engelbrecht MR, Schoorlemmer A, Beuers UHW, Verheij J, Besselink MG, Busch OR, van Gulik TM. Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience. *Langenbecks Arch Surg* 2018; **403**: 289-307 [PMID: 29350267 DOI: 10.1007/s00423-018-1649-2]

68 **Ratti F**, Cipriani F, Fiorentini G, Hidalgo Salinas C, Catena M, Paganelli M, Aldrighetti L. Management of hilum infiltrating tumors of the liver: The impact of experience and standardization on outcome. *Dig Liver Dis* 2019; **51**: 135-141 [PMID: 30115572 DOI: 10.1016/j.dld.2018.07.006]

69 **Olthof PB**, Wiggers JK, Groot Koerkamp B, Coelen RJ, Allen PJ, Besselink MG, Busch OR, D'Angelica MI, DeMatteo RP, Kingham TP, van Lienden KP, Jarnagin WR, van Gulik TM. Postoperative Liver Failure Risk Score: Identifying Patients with Resectable Perihilar Cholangiocarcinoma Who Can Benefit from Portal Vein Embolization. *J Am Coll Surg* 2017; **225**: 387-394 [PMID: 28687509 DOI: 10.1016/j.jamcollsurg.2017.06.007]

70 **Ebata T**, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nagino M. Portal vein embolization before extended hepatectomy for biliary cancer: current technique and review of 494 consecutive embolizations. *Dig Surg* 2012; **29**: 23-29 [PMID: 22441616 DOI: 10.1159/000335718]

71 **Farges O**, Regimbeau JM, Fuks D, Le Treut YP, Cherqui D, Bachellier P, Mabrut JY, Adham M, Pruvot FR, Gigot JF. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. *Br J Surg* 2013; **100**: 274-283 [PMID: 23124720 DOI: 10.1002/bjs.8950]

72 **Celotti A**, Solaini L, Montori G, Coccolini F, Tognali D, Baiocchi G. Preoperative biliary drainage in hilar cholangiocarcinoma: Systematic review and meta-analysis. *Eur J Surg Oncol* 2017; **43**: 1628-1635 [PMID: 28477976 DOI: 10.1016/j.ejso.2017.04.001]

73 **Higuchi R**, Yazawa T, Uemura S, Izumo W, Chaudhary RJ, Furukawa T, Yamamoto M. ENBD is Associated with Decreased Tumor Dissemination Compared to PTBD in Perihilar Cholangiocarcinoma. *J Gastrointest Surg* 2017; **21**: 1506-1514 [PMID: 28721561 DOI: 10.1007/s11605-017-3492-0]

74 **Kloek JJ**, van der Gaag NA, Aziz Y, Rauws EA, van Delden OM, Lameris JS, Busch OR, Gouma DJ, van Gulik TM. Endoscopic and percutaneous preoperative biliary drainage in patients with suspected hilar cholangiocarcinoma. *J Gastrointest Surg* 2010; **14**: 119-125 [PMID: 19756881 DOI: 10.1007/s11605-009-1009-1]

75 **Kawakami H**, Kuwatani M, Onodera M, Haba S, Eto K, Ehira N, Yamato H, Kudo T, Tanaka E, Hirano S, Kondo S, Asaka M. Endoscopic nasobiliary drainage is the most suitable preoperative biliary drainage method in the management of patients with hilar cholangiocarcinoma. *J Gastroenterol* 2011; **46**: 242-248 [PMID: 20700608 DOI: 10.1007/s00535-010-0298-1]

76 **Tang Z**, Yang Y, Meng W, Li X. Best option for preoperative biliary drainage in Klatskin tumor: A systematic review and meta-analysis. *Medicine (Baltimore)* 2017; **96**: e8372 [PMID: 29069029 DOI: 10.1097/MD.0000000000008372]

77 **Coelen RJS**, Roos E, Wiggers JK, Besselink MG, Buis CI, Busch ORC, Dejong CHC, van Delden OM, van Eijck CHJ, Fockens P, Gouma DJ, Koerkamp BG, de Haan MW, van Hooft JE, IJzermans JNM, Kater GM, Koornstra JJ, van Lienden KP, Moelker A, Damink SWMO, Poley JW, Porte RJ, de Ridder RJ, Verheij J, van Woerden V, Rauws EAJ, Dijkgraaf MGW, van Gulik TM. Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. *Lancet Gastroenterol Hepatol* 2018; **3**: 681-690 [PMID: 30122355 DOI: 10.1016/S2468-1253(18)30234-6]

78 **Jo JH**, Chung MJ, Han DH, Park JY, Bang S, Park SW, Song SY, Chung JB. Best options for preoperative biliary drainage in patients with Klatskin tumors. *Surg Endosc* 2017; **31**: 422-429 [PMID: 27287904 DOI: 10.1007/s00464-016-4993-8]

79 **Wiggers JK**, Groot Koerkamp B, van Klaveren D, Coelen RJ, Nio CY, Allen PJ, Besselink MG, Busch OR, D'Angelica MI, DeMatteo RP, Kingham TP, van Gulik TM, Jarnagin WR. Preoperative Risk Score to Predict Occult Metastatic or Locally Advanced Disease in Patients with Resectable Perihilar Cholangiocarcinoma on Imaging. *J Am Coll Surg* 2018; **227**: 238-246.e2 [PMID: 29627334 DOI: 10.1016/j.jamcollsurg.2018.03.041]

80 **Schwegler I**, von Holzen A, Gutzwiller JP, Schlumpf R, Mühlebach S, Stanga Z. Nutritional risk is a clinical predictor of postoperative mortality and morbidity in surgery for colorectal cancer. *Br J Surg* 2010; **97**: 92-97 [PMID: 20013933 DOI: 10.1002/bjs.6805]

81 **Beier-Holgersen R**, Boesby S. Influence of postoperative enteral nutrition on postsurgical infections. *Gut* 1996; **39**: 833-835 [PMID: 9038665 DOI: 10.1136/gut.39.6.833]

82 **Saha SK**, Lee SB, Won J, Choi HY, Kim K, Yang GM, Dayem AA, Cho SG. Correlation between Oxidative Stress, Nutrition, and Cancer Initiation. *Int J Mol Sci* 2017; **18**: 1544 [PMID: 28714931 DOI: 10.3390/ijms18071544]

83 **Akashi K**, Ebata T, Mizuno T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, Nagino M. Surgery for perihilar cholangiocarcinoma from a viewpoint of age: Is it beneficial to octogenarians in an aging society? *Surgery* 2018; **164**: 1023-1029 [PMID: 30082134 DOI: 10.1016/j.surg.2018.05.051]

84 **Pulitano C**, Crawford M, Joseph D, Aldrighetti L, Sandroussi C. Preoperative assessment of postoperative liver function: the importance of residual liver volume. *J Surg Oncol* 2014; **110**: 445-450 [PMID: 24962104 DOI: 10.1002/jso.23671]

85 **Van Der Walt AM**. Patient classification in the Groote Schuur Hospital region, Republic of South Africa. *Nurs Adm Q* 1992; **16**: 43-46 [PMID: 1738490 DOI: 10.1007/s00534-006-1125-1]

86 **Lee EC**, Park SJ, Han SS, Shim JR, Park HM, Lee SD, Kim SH. Risk prediction of post-hepatectomy liver failure in patients with perihilar cholangiocarcinoma. *J Gastroenterol Hepatol* 2018; **33**: 958-965 [PMID: 28843035 DOI: 10.1111/jgh.13966]

87 **Sultana A**, Brooke-Smith M, Ullah S, Figueras J, Rees M, Vauthey JN, Conrad C, Hugh TJ, Garden OJ, Fan ST, Crawford M, Makuuchi M, Yokoyama Y, Büchler M, Padbury R. Prospective evaluation of the International Study Group for Liver Surgery definition of post hepatectomy liver failure after liver resection: an international multicentre study. *HPB (Oxford)* 2018; **20**: 462-469 [PMID: 29287736 DOI: 10.1016/j.hpb.2017.11.007]

88 **Nuzzo G**, Giuliante F, Ardito F, Giovannini I, Aldrighetti L, Belli G, Bresadola F, Calise F, Dalla Valle R, D'Amico DF, Gennari L, Giulini SM, Guglielmi A, Jovine E, Pellicci R, Pernthaler H, Pinna AD, Puleo S, Torzilli G, Capussotti L; Italian Chapter of the International Hepato-Pancreato-Biliary Association, Cillo U, Ercolani G, Ferrucci M, Mastrangelo L, Portolani N, Pulitanò C, Ribero D, Ruzzenente A, Scuderi V, Federico B. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. *Arch Surg* 2012; **147**: 26-34 [PMID: 22250108 DOI: 10.1001/archsurg.2011.771]

89 **Hoyos S**, Navas MC, Restrepo JC, Botero RC. Current controversies in cholangiocarcinoma. *Biochim Biophys Acta Mol Basis Dis* 2018; **1864**: 1461-1467 [PMID: 28756216 DOI: 10.1016/j.bbadis.2017.07.027]

90 **Molina V**, Sampson J, Ferrer J, Díaz A, Ayuso JR, Sánchez-Cabús S, Fuster J, García-Valdecasas JC. Surgical treatment of perihilar cholangiocarcinoma: early results of en bloc portal vein resection. *Langenbecks Arch Surg* 2017; **402**: 95-104 [PMID: 28012034 DOI: 10.1007/s00423-016-1542-9]

91 **Neuhaus P**, Thelen A, Jonas S, Puhl G, Denecke T, Veltzke-Schlieker W, Seehofer D. Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma. *Ann Surg Oncol* 2012; **19**: 1602-1608 [PMID: 21964888 DOI: 10.1245/s10434-011-2077-5]

92 **Benson AB 3rd**, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, Schefter T, Sigurdson ER, Tian GG, Vauthey JN, Venook AP, Yen Y, Zhu AX, Hoffmann KG, McMillian NR, Sundar H. Hepatobiliary cancers, version 2.2014. *J Natl Compr Canc Netw* 2014; **12**: 1152-1182 [PMID: 25099447 DOI: 10.6004/jnccn.2014.0112]

93 **Park Y**, Hwang DW, Kim JH, Hong SM, Jun SY, Lee JH, Song KB, Jun ES, Kim SC, Park KM. Prognostic comparison of the longitudinal margin status in distal bile duct cancer: R0 on first bile duct resection versus R0 after additional resection. *J Hepatobiliary Pancreat Sci* 2019; **26**: 169-178 [PMID: 30849218 DOI: 10.1002/jhbp.619]

94 **Nakanishi Y**, Tsuchikawa T, Okamura K, Nakamura T, Tamoto E, Murakami S, Ebihara Y, Kurashima Y, Noji T, Asano T, Shichinohe T, Hirano S. Prognostic impact of the site of portal vein invasion in patients with surgically resected perihilar cholangiocarcinoma. *Surgery* 2016; **159**: 1511-1519 [PMID: 26948498 DOI: 10.1016/j.surg.2016.01.012]

95 **van Vugt JLA**, Gaspersz MP, Coelen RJS, Vugts J, Labeur TA, de Jonge J, Polak WG, Busch ORC, Besselink MG, IJzermans JNM, Nio CY, van Gulik TM, Willemssen FEJA, Groot Koerkamp B. The prognostic value of portal vein and hepatic artery involvement in patients with perihilar cholangiocarcinoma. *HPB (Oxford)* 2018; **20**: 83-92 [PMID: 28958483 DOI: 10.1016/j.hpb.2017.08.025]

96 **Groot Koerkamp B**, Jarnagin WR. Surgery for perihilar cholangiocarcinoma. *Br J Surg* 2018; **105**: 771-772 [PMID: 29756647 DOI: 10.1002/bjs.10875]

97 **Perini MV**, Coelho FF, Kruger JA, Rocha FG, Herman P. Extended right hepatectomy with caudate lobe resection using the hilar "en bloc" resection technique with a modified hanging maneuver. *J Surg Oncol* 2016; **113**: 427-431 [PMID: 26776500 DOI: 10.1002/jso.24154]

98 **Kawabata Y**, Hayashi H, Yano S, Tajima Y. Liver parenchyma transection-first approach in hemihepatectomy with en bloc caudate lobectomy for hilar cholangiocarcinoma: A safe technique to secure favorable surgical outcomes. *J Surg Oncol* 2017; **115**: 963-970 [PMID: 28334429 DOI: 10.1002/jso.24612]

99 **Ebata T**, Mizuno T, Yokoyama Y, Igami T, Sugawara G, Nagino M. Surgical resection for Bismuth type IV perihilar cholangiocarcinoma. *Br J Surg* 2018; **105**: 829-838 [PMID: 28488733 DOI: 10.1002/bjs.10556]

100 **Hu HJ**, Jin YW, Zhou RX, Shrestha A, Ma WJ, Yang Q, Wang JK, Liu F, Cheng NS, Li FY. Hepatic Artery Resection for Bismuth Type III and IV Hilar Cholangiocarcinoma: Is Reconstruction Always Required? *J Gastrointest Surg* 2018; **22**: 1204-1212 [PMID: 29512002 DOI: 10.1007/s11605-018-3711-3]

101 **Li B**, Xiong XZ, Zhou Y, Wu SJ, You Z, Lu J, Cheng NS. Prognostic value of lymphovascular invasion in Bismuth-Corlette type IV hilar cholangiocarcinoma. *World J Gastroenterol* 2017; **23**: 6685-6693 [PMID: 29085213 DOI: 10.3748/wjg.v23.i36.6685]

102 **Rosen CB**. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Paradigms for Resectable Disease in Annals of Surgery 2018. *Ann Surg* 2018; **267**: 808-809 [PMID: 29465456 DOI: 10.1097/SLA.0000000000002716]

103 **Rizvi S**, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. *Gastroenterology* 2013; **145**: 1215-1229 [PMID: 24140396 DOI: 10.1053/j.gastro.2013.10.013]

104 **Heimbach JK**, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, Rosen CB, Gores GJ. Transplantation for hilar cholangiocarcinoma. *Liver Transpl* 2004; **10**: S65-S68 [PMID: 15382214 DOI: 10.1002/lt.20266]

105 **Rea DJ**, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, Gores GJ, Nagorney DM. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. *Ann Surg* 2005; **242**: 451-8; discussion 458-61 [PMID: 16135931 DOI: 10.1097/01.sla.0000179678.13285.fa]

106 **Ethun CG**, Lopez-Aguiar AG, Anderson DJ, Adams AB, Fields RC, Doyle MB, Chapman WC, Krasnick BA, Weber SM, Mezrich JD, Salem A, Pawlik TM, Poultsides G, Tran TB, Idrees K, Isom CA, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Cardona K, Maithel SK. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease. *Ann Surg* 2018; **267**: 797-805 [PMID: 29064885 DOI: 10.1097/SLA.0000000000002574]

107 **Goldaracena N**, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. *Liver Transpl* 2018; **24**: 294-303 [PMID: 29024405 DOI: 10.1002/lt.24955]

108 **Mansour JC**, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma: expert consensus statement. *HPB (Oxford)* 2015; **17**: 691-699 [PMID: 26172136 DOI: 10.1111/hpb.12450]

109 **Rotellar F**, Pardo F. Laparoscopic staging in hilar cholangiocarcinoma: Is it still justified? *World J Gastrointest Oncol* 2013; **5**: 127-131 [PMID: 23919106 DOI: 10.4251/wjgo.v5.i7.127]

110 **Coelen RJ**, Ruys AT, Wiggers JK, Nio CY, Verheij J, Gouma DJ, Besselink MG, Busch OR, van Gulik TM. Development of a Risk Score to Predict Detection of Metastasized or Locally Advanced Perihilar Cholangiocarcinoma at Staging Laparoscopy. *Ann Surg Oncol* 2016; **23**: 904-910 [PMID: 27586005 DOI: 10.1245/s10434-016-5531-6]

111 **Tian Y**, Liu L, Yeolkar NV, Shen F, Li J, He Z. Diagnostic role of staging laparoscopy in a subset of biliary cancers: a meta-analysis. *ANZ J Surg* 2017; **87**: 22-27 [PMID: 27647697 DOI: 10.1111/ans.13762]

112 **Connor S**, Barron E, Wigmore SJ, Madhavan KK, Parks RW, Garden OJ. The utility of laparoscopic assessment in the preoperative staging of suspected hilar cholangiocarcinoma. *J Gastrointest Surg* 2005; **9**: 476-480 [PMID: 15797226 DOI: 10.1016/j.gassur.2004.10.009]

113 **Ramacciato G**, Nigri G, Bellagamba R, Petrucciani N, Ravaioli M, Cescon M, Del Gaudio M, Ercolani G, Di Benedetto F, Cautero N, Quintini C, Cucchetti A, Lauro A, Miller C, Pinna AD. Univariate and multivariate analysis of prognostic factors in the surgical treatment of hilar cholangiocarcinoma. *Am Surg* 2010; **76**: 1260-1268 [PMID: 21140696]

114 **Aoba T**, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nimura Y, Nagino M. Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes. *Ann Surg* 2013; **257**: 718-725 [PMID: 23407295 DOI: 10.1097/SLA.0b013e3182822277]

115 **Kambakamba P**, Linecker M, Slankamenac K, DeOliveira ML. Lymph node dissection in resectable perihilar cholangiocarcinoma: a systematic review. *Am J Surg* 2015; **210**: 694-701 [PMID: 26212390 DOI: 10.1016/j.amjsurg.2015.05.015]

116 **Kow AW**, Wook CD, Song SC, Kim WS, Kim MJ, Park HJ, Heo JS, Choi SH. Role of caudate lobectomy in type III A and III B hilar cholangiocarcinoma: a 15-year experience in a tertiary institution. *World J Surg* 2012; **36**: 1112-1121 [PMID: 22374541 DOI: 10.1007/s00268-012-1497-0]

117 **Hakeem AR**, Marangoni G, Chapman SJ, Young RS, Nair A, Hidalgo EL, Toogood GJ, Wyatt JI, Lodge PA, Prasad KR. Does the extent of lymphadenectomy, number of lymph nodes, positive lymph node ratio and neutrophil-lymphocyte ratio impact surgical outcome of perihilar cholangiocarcinoma? *Eur J Gastroenterol Hepatol* 2014; **26**: 1047-1054 [PMID: 25051217 DOI: 10.1097/MEG.0000000000000162]

118 **Kiriyama M**, Ebata T, Aoba T, Kaneoka Y, Arai T, Shimizu Y, Nagino M; Nagoya Surgical Oncology Group. Prognostic impact of lymph node metastasis in distal cholangiocarcinoma. *Br J Surg* 2015; **102**: 399-406 [PMID: 25611179 DOI: 10.1002/bjs.9752]

119 **Primrose JN**, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, Wasan H, Ross P, Wall L, Wadsley J, Evans JTR, Stocken D, Praseedom R, Ma YT, Davidson B, Neoptolemos JP, Iveson T, Raftery J, Zhu S, Cunningham D, Garden OJ, Stubbs C, Valle JW, Bridgewater J; BILCAP study group. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. *Lancet Oncol* 2019; **20**: 663-673 [PMID: 30922733 DOI: 10.1016/S1470-2045(18)30915-X]

120 **Edeline J**, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, Boudjema K, Fartoux L, Bouhier-Leporrier K, Jouve JL, Faroux R, Guerin-Meyer V, Kurtz JE, Assénat E, Seitz JF, Baumgaertner I, Tougeron D, de la Fouchardière C, Lombard-Bohas C, Boucher E, Stanbury T, Louvet C, Malka D, Phelip JM. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. *J Clin Oncol* 2019; **37**: 658-667 [PMID: 30707660 DOI: 10.1200/JCO.18.00050]

121 **Stein A**, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klümpen HJ, Lohse AW, Nashan B, Primrose J, Schrum S, Shannon J, Vettorazzi E, Wege H. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. *BMC Cancer* 2015; **15**: 564 [PMID: 26228433 DOI: 10.1186/s12885-015-1498-0]

122 **Horgan AM**, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. *J Clin Oncol* 2012; **30**: 1934-1940 [PMID: 22529261 DOI: 10.1200/JCO.2011.40.5381]

123 **Ghidini M**, Tomasello G, Botticelli A, Barni S, Zabbialini G, Seghezzi S, Passalacqua R, Braconi C, Petrelli F. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. *HPB (Oxford)* 2017; **19**: 741-748 [PMID: 28684194 DOI: 10.1016/j.hpb.2017.05.010]

124 **Messina C**, Merz V, Frisinghelli M, Trentin C, Grego E, Veccia A, Salati M, Messina M, Carnaghi C, Caffo O. Adjuvant chemotherapy in resected bile duct cancer: A systematic review and meta-analysis of randomized trials. *Crit Rev Oncol Hematol* 2019; **143**: 124-129 [PMID: 31563828 DOI: 10.1016/j.critrevonc.2019.09.002]

125 **Nassour I**, Mokdad AA, Porembka MR, Choti MA, Polanco PM, Mansour JC, Minter RM, Wang SC, Yopp AC. Adjuvant Therapy Is Associated With Improved Survival in Resected Perihilar Cholangiocarcinoma: A Propensity Matched Study. *Ann Surg Oncol* 2018; **25**: 1193-1201 [PMID: 29488187 DOI: 10.1245/s10434-018-6388-7]

126 **Phelip JM**, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, Michel P, Le Malicot K, Smith D, Seitz JF, Fauchart JP, Martin P, Bennouna J, Morin T, Bonnet I, Maingon P, Lepage C, Chauffert B. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. *Eur J Cancer* 2014; **50**: 2975-2982 [PMID: 25241229 DOI: 10.1016/j.ejca.2014.08.013]

127 **Fuller CD**, Dang ND, Wang SJ, Desai P, Choi M, Thomas CR Jr, Fuss M. Image-guided intensity-modulated radiotherapy (IG-IMRT) for biliary adenocarcinomas: Initial clinical results. *Radiother Oncol* 2009; **92**: 249-254 [PMID: 19324442 DOI: 10.1016/j.radonc.2009.02.015]

128 **Valle J**, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N Engl J Med* 2010; **362**: 1273-1281 [PMID: 20375404 DOI: 10.1056/NEJMoa0908721]

129 **Valle JW**, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, Bridgewater J, Okusaka T. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. *Ann Oncol* 2014; **25**: 391-398 [PMID: 24351397 DOI: 10.1093/annonc/mdt540]

130 **Lamarca A**, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. *Ann Oncol* 2014; **25**: 2328-2338 [PMID: 24769639 DOI: 10.1093/annonc/mdu162]

131 **Fornaro L**, Vivaldi C, Cereda S, Leone F, Aprile G, Lonardi S, Silvestris N, Santini D, Milella M, Caparello C, Musettini G, Pasquini G, Falcone A, Brandi G, Sperduti I, Vasile E; GICO group (Gruppo Italiano COlangiocarcinoma). Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. *J Exp Clin Cancer Res* 2015; **34**: 156 [PMID: 26693938 DOI: 10.1186/s13046-015-0267-x]

132 **Lamarca A**, Palmer DH, Singh Wasan H, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, Anthoney A, Maraveyas A, Waters JS, Hobbs C, Barber S, Ryder D, Ramage J, Davies LM, Bridgewater JA, Valle JW. ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. *J Clin Oncol* 2019; **37**: 4003 [DOI: 10.1200/JCO.2019.37.15\_suppl.4003]

133 **Abou-Alfa GK,** Mercade TM, Javle M, Kelley RK, Lubner S, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant J, Wu B, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. LBA10\_PR - ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. *Ann Oncol* 2019; **30**: v872-v873 [DOI: 10.1093/annonc/mdz394.027]

134 **Indar AA**, Lobo DN, Gilliam AD, Gregson R, Davidson I, Whittaker S, Doran J, Rowlands BJ, Beckingham IJ. Percutaneous biliary metal wall stenting in malignant obstructive jaundice. *Eur J Gastroenterol Hepatol* 2003; **15**: 915-919 [PMID: 12867803 DOI: 10.1097/00042737-200308000-00013]

135 **Cui P**, Pang Q, Wang Y, Qian Z, Hu X, Wang W, Li Z, Zhou L, Man Z, Yang S, Jin H, Liu H. Nutritional prognostic scores in patients with hilar cholangiocarcinoma treated by percutaneous transhepatic biliary stenting combined with 125I seed intracavitary irradiation: A retrospective observational study. *Medicine (Baltimore)* 2018; **97**: e11000 [PMID: 29851859 DOI: 10.1097/MD.0000000000011000]

136 **Groot Koerkamp B**, Wiggers JK, Allen PJ, Besselink MG, Blumgart LH, Busch OR, Coelen RJ, D'Angelica MI, DeMatteo RP, Gouma DJ, Kingham TP, Jarnagin WR, van Gulik TM. Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection. *J Am Coll Surg* 2015; **221**: 1041-1049 [PMID: 26454735 DOI: 10.1016/j.jamcollsurg.2015.09.005]

137 **Buettner S**, van Vugt JL, Gani F, Groot Koerkamp B, Margonis GA, Ethun CG, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick B, Weber SM, Salem A, Martin RC, Scoggins C, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Maithel SK, Guglielmi A, IJzermans JN, Pawlik TM. A Comparison of Prognostic Schemes for Perihilar Cholangiocarcinoma. *J Gastrointest Surg* 2016; **20**: 1716-1724 [PMID: 27412318 DOI: 10.1007/s11605-016-3203-2]

138 **Lurje G**, Bednarsch J, Czigany Z, Lurje I, Schlebusch IK, Boecker J, Meister FA, Tacke F, Roderburg C, Den Dulk M, Gaisa NT, Bruners P, Neumann UP. The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma. *Eur J Surg Oncol* 2019; **45**: 1468-1478 [PMID: 31053477 DOI: 10.1016/j.ejso.2019.04.019]

139 **Natsume S**, Ebata T, Yokoyama Y, Igami T, Sugawara G, Shimoyama Y, Nagino M. Clinical significance of left trisectionectomy for perihilar cholangiocarcinoma: an appraisal and comparison with left hepatectomy. *Ann Surg* 2012; **255**: 754-762 [PMID: 22367444 DOI: 10.1097/SLA.0b013e31824a8d82]

140 **Lehrke HD**, Heimbach JK, Wu TT, Jenkins SM, Gores GJ, Rosen CB, Mounajjed T. Prognostic Significance of the Histologic Response of Perihilar Cholangiocarcinoma to Preoperative Neoadjuvant Chemoradiation in Liver Explants. *Am J Surg Pathol* 2016; **40**: 510-518 [PMID: 26752544 DOI: 10.1097/PAS.0000000000000588]

141 **Darwish Murad S**, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, Botha JF, Mezrich JD, Chapman WC, Schwartz JJ, Hong JC, Emond JC, Jeon H, Rosen CB, Gores GJ, Heimbach JK. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. *Gastroenterology* 2012; 143: 88-98.e3 [PMID: 22504095 DOI: 10.1053/j.gastro.2012.04.008]

142 **Darwish Murad S**, Kim WR, Therneau T, Gores GJ, Rosen CB, Martenson JA, Alberts SR, Heimbach JK. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. *Hepatology* 2012; **56**: 972-981 [PMID: 22290335 DOI: 10.1002/hep.25629]

**Footnotes**

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited Manuscript

**Corresponding Author's Membership in Professional Societies:**

**Peer-review started:** December 31, 2019

**First decision:** January 16, 2020

**Article in press:** June 19, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P- Reviewer:** Yi PS,Zeng YY **S- Editor:** Zhang H **L- Editor:** **E- Editor:Ma YJ**

**Figure Legends**

****

**Figure 1 Schematic representation of extrahepatic and intrahepatic bile ducts (until second order) showing Bismuth-Corlette classification.** CCC: Cholangiocarncioma.



**Figure 2** **Diagnostic and therapeutic work-flow for** **perihilar** **cholangiocarncioma.** 1if cytological confirmation is needed (negative carbohydrate antigen 19-9, positive immunoglobulin G4, and confounding diagnosis at imaging); interrupted line, consider neo-adjuvant therapies. US: Ultrasound; CT: Computed tomography; MR: Magnetic resonance; CA 19-9: Carbohydrate antigen 19-9; BIL: Bilirubin; IgG4: Immunoglobulin G4; ERCP: Endoscopic-retrograde-pancreatoduodenoscopy; EUS: Endoscopic ultrasound; FRL: Future remnant liver; PVE: Portal vein embolization; ALPPS: Associated liver partition to portal vein ligation for staged hepatectomy; PTC: Percutaneous transhepatic colangiography; CHT: chemotherapy; RT: radiotherapy.

**Table 1 Patients that should undergo to screening programs and the techniques that should be applied**

|  |  |  |
| --- | --- | --- |
| **Predisposing factors** | **Diagnostic technique** | **Worrisome features** |
| Intrahepatic lithiasis and recurrent pyogenic cholangitis | MR | Stenosis progression, distal bile duct dilatation, intraductal polypoid mass > 1 cm. |
| PSC | MR + ERCP | Irregular bile duct stenosis, bilateral bile duct dilatation, ipsilateral lobar atrophy. ERCP bile duct sampling can simplify differential diagnosis. |
| Intrahepatic fluke | US/MR | Central intrahepatic and main bile duct dilation with stenosis identificationa. |

MR: Magnetic resonance; PSC: Primary sclerosing cholangitis; ERCP: Endoscopic retrograde pacreatoduodenoscopy; US: Ultrasound. a: Ultrasound, computed tomography and magnetic resonance findings for intrahepatic fluke are diffuse and uniform dilatation of peripheral intrahepatic bile ducts with no dilatation of central intrahepatic and main bile ducts, without focal obstruction lesions, with increased echogenity of bile ducts and non-shadowing echogenic foci within bile ducts (eggs or flukes).

**Table 2 Main advantages of two the two techniques available to obtain bile duct drainage**

|  |  |
| --- | --- |
| **ERCP** | **PTC** |
| Internal stent: less patient discomfort[5]  | External drainage: increased patient discomfort[5] |
| Reduced risk of seeding[73] | Higher expertise needed[108] |
| Higher rate of bacterial contamination/cholangitis[76] | Higher rate of hemorrhage[76] |
| “One shot” microbiological examination | Never cross the malignant bile duct stenosis[5] |
| Removed during surgery | Repeated cholangiography and microbiological samples  |
|   | Useful during and after surgery  |

ERCP: Endoscopic retrograde pacreatoduodenoscopy; PTC: Percutaneous transhepatic colangiography.

**Table 3 Criteria that can be used to identify non-resectable patients**

|  |  |
| --- | --- |
| **Absolute criteria** | **Relative criteria** |
| **Criteria** | **Suggestions** |
| Presence of distant metastasis (especially liver, lung, peritoneum) | Longitudinal and lateral dissemination  | Consider adequate staging (avoid R1-2) |
| Extra-regional lymphnode involvement (para-aortic and extraperitoneal) |
| Bilateral intrahepatic involvement of biliary tree that exclude bilio-enteric anastomosis | Portal infiltration < 2 cm | Portal vein resection needed |
| Infiltration or occlusion of the main portal trunk proximal to bifurcation |
| Right lobe atrophy associated to contralateral portal vein infiltration or portal occlusion > 2 cm | Low remant liver | Consider liver hypertrophy techniques |
| Right lobe atrophy associated to contralateral tumor extension more than to 2 cm from hepatic hilum |
| Contralateral invasion of hepatic artery | Type IV pCCC | High expertise; consider en-bloc resection |
| Unilobar secondary bile ducts invasion associated to contralateral infiltration or collusion of portal vein |

pCCC: Perihilar cholangiocarncioma.

**Table 4** **Articles reporting resection of type IV perihilar cholangiocarncioma according** **di bismuth**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Publication year** | **Resection rate (%)** | **Resected cases (*n*)** | **Vascular resection (*n*)** | **Vascular reconstruction (*n*)** | **Vascular invasion at histological evaluation (*n*)** | **Complications (%)** | **N+ (%)** | **R0 (%)** | **Patient survival 1-3-5 yr (%)** |
| Hu HJ | 2018 | na | 69 | 52 | 14 | 63 | 39 | 57 | 86 | 76-44-22 |
| Li B | 2017 | na | 142 | 42 | na | na | na | 37 | 75 | 35-12-3 |
| Ebata T | 2018 | 50 | 216 | 131 | na | 136 PV + 53 HA | 19 | 20 | 72 | 68-34-22 |
| Ji GW | 2017 | na | 25 | 4 | 4 | 13 | 13 | 76 | 95 | na |
| Hoffman K | 2015 | na | 31 (+29 tipo II e III) | 311,2 | 211 | 19 | 52 | 36 | 60 | 84-38-181 |
| Han IW | 2014 | 21 | 33 | 6 | na | 12 PV + 13 HA | na | 36 | 54 | na-28-na |
| Cheng QB | 2012 | 61  | 101 (+75 tipo III) | na | na | na | 25 | 40 | 76 | 89-38-133 |

We selected only the series were data on type IV resection can be extract. 1Added type II and III cases. 2All cases with presumed vascular infiltration had vascular resection, while only 19 cases had histological proven vascular infiltration. 3Added type III cases. PV: Portal vein; HA: Hepatic artery. na: Not applicable.